NEW YORK (GenomeWeb News) - Oxford Genome Sciences said last weekthat it is collaborating with Amgen to discover, develop, and commercialize therapeutic antibodies for cancer.
The companies will use Amgen’s XenoMouse technology to generate fully human anibodies, which will be raised against druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project database of cancer proteins.
The agreement covers up to six oncology programs. Amgen has the right to select up to three programs while Oxford Genome Sciences retains the rights to the rest. After Amgen has produced the initial antibody leads, Oxford Genome will carry out the initial pre-clinical assessment of each antibody program.
Further terms of the deal were not disclosed.